Li Zhou, VP Cell Engineering at TxCell, to co-chair the Treg session
TxCell’s academic partner Ignacio Anegon, from INSERM, to give oral presentation on CD8+ Tregs
Valbonne, France, October 4, 2017, 6.30pm CEST
TxCell SA (FR0010127662 – TXCL), a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, today announces its participation at the Final Conference of the European COST Consortium ‘Action to Focus & Accelerate Cell-based Tolerogenic Therapies’ (A FACTT) to be held on October 9-11, 2017 in Barcelona, Spain.
Li Zhou, PhD, Vice President Cell Engineering at TxCell, will be co-chairing the session dedicated to regulatory T cells taking place on October 9, 2017 at 11.45am CEST. Li Zhou will make an introduction on TxCell’s CAR-Treg technology at the start of the session.
In addition, Ignacio Anegon, MD, INSERM scientist and co director of team number 2 at the Center for Research in Transplantation and Immunology (CRTI, Nantes, France), will give an oral presentation entitled ‘CD8+ Treg new players in allograft tolerance’ on October 9, 2017, at 2.40pm CEST.
In December 2016, TxCell gained exclusive worldwide rights to two patent families covering the new type of CD8+ Tregs identified by the CRTI for all autoimmune diseases and transplantation-related disorders.
The full conference program is available on the conference website www.afactt.eu.